Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3326 views | HTML 3112 views | ?
Anja Heinemann1,2,3, Carleen Cullinane4, Ricardo De Paoli-Iseppi2,5, James S. Wilmott2,5, Dilini Gunatilake1,2,3, Jason Madore2,5, Dario Strbenac6, Jean Y. Yang6, Kavitha Gowrishankar1,2, Jessamy C. Tiffen1,2,3, Rab K. Prinjha7, Nicholas Smithers7, Grant A. McArthur4, Peter Hersey1,2,3, Stuart J. Gallagher1,2,3
1Melanoma Research Group, Kolling Institute of Medical Research, University of Sydney, St Leonards NSW, Australia
2Melanoma Institute of Australia, North Sydney, NSW, Australia
3Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, NSW, Australia
4Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
5Sydney Medical School, University of Sydney, Sydney, NSW, Australia
6School of Mathematics and Statistics, University of Sydney, Sydney NSW, Australia
7Epinova Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom
Stuart J. Gallagher, e-mail: [email protected]
Keywords: panobinostat, I-BET151, melanoma, bromodomain, epigenetic
Received: February 17, 2015 Accepted: May 23, 2015 Published: June 05, 2015
Histone acetylation marks have an important role in controlling gene expression and are removed by histone deacetylases (HDACs). These marks are read by bromodomain and extra-terminal (BET) proteins and novel inhibitiors of these proteins are currently in clinical development. Inhibitors of HDAC and BET proteins have individually been shown to cause apoptosis and reduce growth of melanoma cells. Here we show that combining the HDAC inhibitor LBH589 and BET inhibitor I-BET151 synergistically induce apoptosis of melanoma cells but not of melanocytes. Induction of apoptosis proceeded through the mitochondrial pathway, was caspase dependent and involved upregulation of the BH3 pro-apoptotic protein BIM. Analysis of signal pathways in melanoma cell lines resistant to BRAF inhibitors revealed that treatment with the combination strongly downregulated anti-apoptotic proteins and proteins in the AKT and Hippo/YAP signaling pathways. Xenograft studies showed that the combination of inhibitors was more effective than single drug treatment and confirmed upregulation of BIM and downregulation of XIAP as seen in vitro. These results support the combination of these two classes of epigenetic regulators in treatment of melanoma including those resistant to BRAF inhibitors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.